Delivery Order SPE2DB24D2205-SPE2DB25FEFTX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Mekinist 2 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $9,670.51 and is scheduled for completion by August 26, 2025. The contract is not subject to any small business set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a $8.55K delivery order to AmerisourceBergen Drug Corp for Mekinist 0.5 mg tablets (30-count units) under a firm fixed price contract. This non-set-aside competitive award was issued on July 23, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy medication, reflecting the breadth of pharmaceutical products procured...
- The Defense Logistics Agency awarded a delivery order valued at $11,403.32 to AmerisourceBergen Drug Corp for the supply of Mekinist 0.5 mg tablets (30-count units). The contract, awarded July 21, 2025, carries a firm fixed price and is scheduled for completion by August 11, 2025. This is a non-set-aside, competitively awarded delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global...
- This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the drug Mekinist 2 mg Tablet, with a total ceiling value of $9,670.51 and a period of performance through July 28, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $19,341.02, is for the supply of Mekinist 2 mg tablets to support federal healthcare programs. The contract is a firm fixed-price delivery order with a period of performance through February 27, 2025. It was awarded on February 5, 2025 and does not have a set-aside designation, indicating open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mekinist 0.05 mg/ml solution (90 ml) under a firm fixed-price contract valued at $5,576.15, with an ultimate completion date of August 19, 2025. This competitively awarded, non-set-aside delivery order represents a pharmaceutical supply transaction supporting federal medical procurement needs. The place of performance is listed as Conshohocken, Pennsylvania, which is also the headquarters location of...
- This is a delivery order under a Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) awarded to AmerisourceBergen Drug Corp's Corporate Office division. The contract, valued at up to $999,999,999 through December 2025, provides a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. This specific delivery order, valued at $8,878.79, is for the Mekinist 2 mg tablet drug product. The...
- This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,714.72 fixed-price delivery order is for the supply of MEKINIST 0.5 MG TABLET medical products, with a period of performance through July 31, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The $9,670.51 firm fixed-price delivery order is for the supply of MEKINIST 2 MG TABLET, a pharmaceutical product. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of the pharmaceutical product MEKINIST 2 MG TABLET UU 30S, with a ceiling value of $19,341.02 and a performance period through June 2, 2025. The contract is designated as a Firm Fixed Price Delivery Order, without any set-aside requirements. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFTXDelivery Order
The Defense Logistics Agency awarded a $9,670.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mekinist 2 mg tablets (30-count units) on August 4, 2025, with an ultimate completion date of August 25, 2025. This contract represents a non-set-aside, competitively awarded delivery order executed by the prime contractor's Corporate Office, located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying a wide range of brand-name and generic medications to support military and veteran healthcare systems. Mekinist, a targeted cancer therapy, represents one of the specialized medications within the company's extensive portfolio of pharmaceutical products delivered through the DLA Medical Supply Chain. The non-set-aside award demonstrates AmerisourceBergen Drug Corp's competitive capability in federal procurement, consistent with its role as a primary vendor supporting the Defense Health Agency and other government healthcare systems through flexible contract vehicles designed to meet global pharmaceutical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.7k | 8/4/25 |